Corcept Therapeutics Incorporated (CORT)
Interest coverage
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | — | 107,282 | 112,634 | 124,477 | 128,202 |
| Interest expense | US$ in thousands | — | — | 3,557 | 3,596 | 5,637 |
| Interest coverage | — | — | 31.67 | 34.62 | 22.74 |
December 31, 2024 calculation
Interest coverage = EBIT ÷ Interest expense
= $—K ÷ $—K
= —
The interest coverage ratio for Corcept Therapeutics Incorporated has shown a positive trend over the years from 2020 to 2022. In 2020, the interest coverage ratio was 22.74, indicating that the company generated 22.74 times the operating income needed to cover its interest expenses. This ratio improved to 34.62 in 2021 and further to 31.67 in 2022, reflecting the company's strong ability to meet its interest obligations comfortably.
However, it is worth noting that the data is unavailable for the years 2023 and 2024. It would be essential for investors and stakeholders to monitor future interest coverage ratios to ensure the company maintains its ability to service its debt obligations effectively. Overall, the increasing trend in the interest coverage ratio signifies Corcept Therapeutics Incorporated's improved financial stability and capacity to handle its interest expenses.
Peer comparison
Dec 31, 2024